

# Pharmaceutical Drugs Industry: Global Competitive Landscape 2021

<https://marketpublishers.com/r/P86397F0122AEN.html>

Date: October 2022

Pages: 307

Price: US\$ 5,500.00 (Single User License)

ID: P86397F0122AEN

## Abstracts

### Report Scope:

This research report incorporates an in-depth analysis of the pharmaceutical drugs market and its competitive landscape through 2021. Major players, competitive intelligence, innovative technologies and company profiles are discussed in detail. The report also examines recent developments and product portfolios of major players, and it features market share analysis and rankings in the market. It includes a regulatory landscape analysis that focuses on recent regulations in regions such as the U.S., Europe and Japan.

### Report Includes:

71 data tables and 54 additional tables

A brief general overview of the global pharmaceutical drugs industry competitive landscape

Analyses of the global market trends, with historic market revenue for 2016 to 2021, estimates for 2022, market forecasts for 2022-2026, and projections of compound annual growth rates (CAGRs) through 2027

Assessment of major driving factors, opportunities and challenges in this innovation driven market, with emphasis on recent developments in the pharmaceutical industry

Highlights of the current and future market potential of pharmaceutical industry

along with a detailed analysis of the competitive environment, regulatory scenario and clinical trails

Discussion of the industry value chain analysis providing a systematic study of key intermediaries involved, with emphasis on recent developments and region-specific macroeconomic factors on global pharmaceutical drugs marketplace

Market assessment of the COVID-19 impact on the global pharmaceutical drugs market, along with its implications on demand and supply, price impact and various government strategic decisions

Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues

Descriptive company profiles of the leading pharma manufacturers, including Abbott, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline PLC, Pfizer Inc., Sanofi Corp., Takeda Pharmaceutical Co. Ltd. and Zydus Cadila

## Contents

### CHAPTER 1 INTRODUCTION

- 1.1 Study Goals and Objectives
- 1.2 Reasons for Doing This Study
- 1.3 Scope of Report
- 1.4 Methodology
  - 1.4.1 Primary Data and Information Gathering
  - 1.4.2 Secondary Data and Information Gathering
- 1.5 Market Revenue Forecasts
- 1.6 Analyst's Credentials
- 1.7 BCC Custom Research
- 1.8 Related BCC Research Reports

### CHAPTER 2 MARKET AND TECHNOLOGY BACKGROUND

- 2.1 Background and Definitions: Pharmaceutical Drugs
- 2.2 Uses of Various Drugs
- 2.3 Background: Innovation in the Pharmaceutical Industry
- 2.4 Stakeholders Involved in the Innovation Process
- 2.5 The Pharmaceutical Industry
- 2.6 The Cost of Pharmaceutical Drug Innovation
- 2.7 Current Trends in the Pharmaceuticals Industry
  - 2.7.1 Digital Transformation and Technological Developments
  - 2.7.2 Increasing R&D Spend and Shift Toward Modern Therapeutics and Technologies
  - 2.7.3 Collaborations for Advanced Therapeutics
  - 2.7.4 Market Consolidation for Strategic Growth and to Retain Market Leadership
- 2.8 Notable Trends
  - 2.8.1 Income Growth in Developing Markets
  - 2.8.2 Changing Structure of the Pharma and Healthcare Industry
  - 2.8.3 Lifestyle Medicine
  - 2.8.4 Patient-Centric Programs
  - 2.8.5 Prevalence of Self-Care
  - 2.8.6 Burden on Public Health System
- 2.9 Importance of Innovation
- 2.10 Challenges Facing the Sector
  - 2.10.1 Public Health Systems
  - 2.10.2 Balancing Patient Needs and Financial Sustainability

- 2.10.3 Competitiveness and Innovation
- 2.11 Market Dynamics
  - 2.11.1 Drivers
  - 2.11.2 Restraints
- 2.12 Opportunities
- 2.13 Strategies
- 2.14 Distribution Network
  - 2.14.1 Asia-Pacific
  - 2.14.2 U.S.
  - 2.14.3 Europe
  - 2.14.4 India
  - 2.14.5 China
  - 2.14.6 Japan
  - 2.14.7 South Korea
- 2.15 Recommendations

## **CHAPTER 3 IMPACT OF COVID-19 ON THE PHARMACEUTICAL DRUG MARKET**

- 3.1 Overview
- 3.2 COVID-19 Crisis
- 3.3 Impact on Market
- 3.4 Current Outlook
  - 3.4.1 Implications on Cancer Diagnosis
  - 3.4.2 Implications on Cancer Treatment
  - 3.4.3 Impact on Oncology Pharmaceuticals Market
- 3.5 Implications on Cancer Treatment
  - 3.5.1 Key Impacts of COVID-19

## **CHAPTER 4 REGULATORY STRUCTURE: PHARMACEUTICAL DRUG MARKET**

- 4.1 Regulatory Background
- 4.2 Regulatory Systems for Biopharmaceuticals by Region
  - 4.2.1 U.S.
  - 4.2.2 Europe
  - 4.2.3 Japan
- 4.3 Regulatory Systems for Pharmaceuticals by Region
  - 4.3.1 U.S.
  - 4.3.2 Japan
  - 4.3.3 India

- 4.3.4 Brazil
- 4.4 Regulations for Vaccines
  - 4.4.1 Current Regulatory Issues for Vaccines
  - 4.4.2 Moderna Vaccine Regulation in the U.K.
- 4.5 Key Regulatory Updates, 2020
  - 4.5.1 Pharmaceuticals
  - 4.5.2 Medical Devices
- 4.6 Code of Federal Regulations (CFR)
- 4.7 Good Manufacturing Compliance (GMP) Compliance
- 4.8 Establishment Registration
- 4.9 Drug Registration and Listing
- 4.10 Local Agent Requirements
  - 4.10.1 Responsibilities of the U.S. Agent

## **CHAPTER 5 PRICING AND REIMBURSEMENT: PHARMACEUTICALS AND BIOLOGICS**

- 5.1 Pricing and Reimbursement Background
- 5.2 Pricing and Reimbursement of Pharmaceuticals and Biologics by Region
  - 5.2.1 U.S.
  - 5.2.2 Europe
  - 5.2.3 Japan
- 5.3 Pricing and Reimbursement Challenges for Pharmaceuticals
  - 5.3.1 Patented Medicines Price
  - 5.3.2 Prices of Older Drugs
- 5.4 Pricing and Reimbursement for Medical Devices by Region
  - 5.4.1 U.S.
  - 5.4.2 Europe
  - 5.4.3 Japan
- 5.5 Other Parts of Asia-Pacific

## **CHAPTER 6 PHARMACEUTICAL DRUGS INDUSTRY: COMPETITIVE LANDSCAPE**

- 6.1 Overview
- 6.2 Key Strategies of Major Pharmaceutical Drugs Manufacturers
  - 6.2.1 Distribution Network
  - 6.2.2 Trends
  - 6.2.3 Mergers and Acquisitions
  - 6.2.4 Recommendations

## 6.3 Key Developments of the Major Pharmaceutical Drugs Manufacturers

### 6.3.1 Mergers and Acquisitions in Pharmaceutical Drugs Market

### 6.3.2 Agreements, Joint Ventures, Expansions, Divestments and Investments, Pharmaceuticals Market

### 6.3.4 New Product Launches and Approvals

## 6.4 Long-Term Outlook

## **CHAPTER 7 COMPANY PROFILES**

ABBOTT

ABBVIE INC.

ALEXION PHARMACEUTICALS INC.

AMGEN INC.

ASTELLAS PHARMA INC.

ASTRAZENECA

ASAHI KASEI CORP.

AUROBINDO PHARMA

BAUSCH HEALTH COMPANIES INC.

BAYER AG

BIOGEN

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

BRISTOL MYERS SQUIBB COMPANY

CHUGAI PHARMACEUTICAL CO. LTD.

CSL LTD.

DAIICHI SANKYO CO. LTD.

DR. REDDY'S LABORATORIES LTD.

EISAI CO. LTD.

ELI LILLY AND CO.

ENDO INTERNATIONAL PLC

GILEAD SCIENCES INC.

GLAXOSMITHKLINE PLC

GRIFOLS S.A.

H. LUNDBECK A/S

INCYTE

IPSEN PHARMA

JOHNSON & JOHNSON SERVICES INC.

MALLINCKRODT PLC

A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L.

MERCK & CO. INC.

MERCK KGAA  
MODERNA INC.  
NOVARTIS AG  
NOVO NORDISK A/S  
OTSUKA HOLDINGS CO. LTD.  
PFIZER INC.  
REGENERON PHARMACEUTICALS INC.  
F. HOFFMANN-LA ROCHE LTD. (ROCHE)  
SANOFI  
SERVIER LABORATORIES  
SHANGHAI PHARMACEUTICALS HOLDING  
SHIONOGI & CO. LTD.  
CHINA NATIONAL PHARMACEUTICAL GROUP CORP. (SINOPHARM)  
STADA ARZNEIMITTEL AG  
SUMITOMO PHARMA CO. LTD.  
SUN PHARMACEUTICAL INDUSTRIES LTD.  
TAKEDA PHARMACEUTICAL CO. LTD.  
TEVA PHARMACEUTICAL INDUSTRIES LTD.  
UCB S.A.  
VERTEX PHARMACEUTICALS INC.  
VIATRIS INC.  
ZYDUS CADILA

## List Of Tables

### LIST OF TABLES

- Table 1: Top 20 Pharmaceutical Companies, R&D Expenditures, 2021
- Table 2: Trends in Per Capita Real Gross Domestic Product Growth, by Region, 2016-2019
- Table 3: Countries/Region that Authorized Moderna's Vaccine for COVID-19
- Table 4: Standard Vaccine Pricing Process in the U.S.
- Table 5: COVID-19 Vaccine Price Range in the U.S., by Federal Government Purchase
- Table 6: Global Pharmaceutical Drug Manufacturers Market Share, 2021
- Table 7: Global Pharmaceutical Drug Manufacturers Key Financials 2021
- Table 8: Global Pharmaceutical Drug Manufacturers R&D Expenditure and % of R&D in Revenue, by Company, 2021
- Table 9: Top 50 Best-Selling Pharmaceuticals, 2021
- Table 10: Global Market for Pharmaceutical Drugs, 2016-2020
- Table 11: Global Market for Pharmaceutical Drugs, Through 2027
- Table 12: Global Market for Pharmaceutical Drugs, by Region, 2016-2020
- Table 13: Global Market for Pharmaceutical Drugs, by Region, Through 2027
- Table 14: Certification, Reorganization, R&D Facilities and Services and Solutions in the Pharmaceuticals Market
- Table 15: Abbott: Financials, 2016-2021
- Table 16: Abbott: Product Portfolio, by Business Segment 2021
- Table 17: Abbott: Recent Developments, 2015-2020
- Table 18: AbbVie: Oncology Pharmaceutical Product Portfolio
- Table 19: AbbVie: Oncology Pharmaceutical Revenue, 2018-2020
- Table 20: AbbVie Inc.: Marketed Products
- Table 21: AbbVie Inc.: Business Segment
- Table 22: AbbVie Inc.: Financial Performance, 2018-2021
- Table 23: AbbVie Inc.: Key Developments
- Table 24: Alexion: Financial Performance, 2020
- Table 25: Alexion: Key Developments
- Table 26: Amgen: Financial Performance, 2018-2021
- Table 27: Amgen: Financials, 2014-2021
- Table 28: Amgen: Oncology Pharmaceuticals Product Portfolio
- Table 29: Amgen: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 30: Amgen: Key Developments
- Table 31: Astellas: Key Financials 2021
- Table 32: Astellas: Oncology Pharmaceuticals Product Portfolio



- Table 33: Astellas: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 34: Astellas: Key Developments
- Table 35: AstraZeneca: Financial Performance, 2018-2021
- Table 36: AstraZeneca: Oncology Pharmaceuticals Product Portfolio
- Table 37: AstraZeneca: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 38: Aurobindo Pharma: Financial Performance, 2021
- Table 39: Bausch Health Companies Inc.: Product Portfolio of Dermatology Devices
- Table 40: Bayer AG: Marketed Products
- Table 41: Bayer AG: Oncology Pharmaceuticals Product Portfolio
- Table 42: Bayer AG: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 43: Bayer AG: Key Financials, 2021
- Table 44: Biogen: Key Financials, 2021
- Table 45: Bristol-Myers Squibb: Financial Performance, 2018-2021
- Table 46: Bristol-Myers Squibb: Oncology Pharmaceuticals Product Portfolio
- Table 47: Bristol-Myers Squibb: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 48: CSL Ltd. (Seqirus): Vaccines Offered
- Table 49: CSL Ltd. (Seqirus): Recent Developments
- Table 50: Daiichi Sankyo Co. Ltd.: Net Revenue 2021
- Table 51: Dr. Reddy's: Key Financials 2021
- Table 52: Eisai: Key Financials, 2021
- Table 53: Eli Lilly and Co.: Business Segments
- Table 54: Eli Lilly and Co.: Marketed Osteoporosis Products
- Table 55: Eli Lilly and Co.: Financial Performance, 2018-2021
- Table 56: Eli Lilly and Co.: Oncology Pharmaceuticals Product Portfolio
- Table 57: Eli Lilly and Co.: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 58: Endo International: Key Financials, 2021
- Table 59: Gilead Sciences Inc.: Oncology Pharmaceuticals Product Portfolio
- Table 60: Gilead Sciences Inc.: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 61: Gilead Sciences: Key Financials, 2021
- Table 62: GlaxoSmithKline PLC: Product Segment
- Table 63: GlaxoSmithKline PLC: Key Financials, 2021
- Table 64: GlaxoSmithKline PLC: Vaccines Offered
- Table 65: GlaxoSmithKline PLC: Flu Vaccines Sales
- Table 66: GlaxoSmithKline PLC: Recent Developments
- Table 67: Grifols SA: Product Portfolio
- Table 68: Lundbeck: Key Financials, 2021
- Table 69: Incyte: Key Financials, 2021
- Table 70: Ipsen: Key Financials, 2021
- Table 71: Johnson & Johnson: Business Segments

- Table 72: Johnson & Johnson: Financials, 2021
- Table 73: Johnson & Johnson: Financial Performance, 2018-2021
- Table 74: Johnson & Johnson: Product Description
- Table 75: Johnson & Johnson: Recent Developments and Strategies
- Table 76: Mallinckrodt: Key Financials, 2021
- Table 77: Menarini Group: Key Financials, 2021
- Table 78: Merck & Co. Inc.: Business Segment
- Table 79: Merck & Co. Inc.: Financial Performance, 2018-2021
- Table 80: Merck KGaA: Key Financials, 2021
- Table 81: Moderna: Key Financials, 2021
- Table 82: Novartis: Oncology Pharmaceuticals Product Portfolio
- Table 83: Novartis: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 84: Novartis: Key Financials, 2021
- Table 85: Novartis Key Developments
- Table 86: Novo Nordisk: Product Portfolio
- Table 87: Novo Nordisk: Key Financials, 2021
- Table 88: Otsuka Holdings Co. Ltd.: Key Financials, 2021
- Table 89: Otsuka Holdings Co. Ltd.: Key Developments
- Table 90: Pfizer: Product Segments
- Table 91: Pfizer: Oncology Pharmaceuticals Product Portfolio
- Table 92: Pfizer: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 93: Pfizer: Women's Health-Marketed Products by Indication
- Table 94: Pfizer: Key Financials, 2021
- Table 95: Regeneron: Key Financials, 2021
- Table 96: Roche: Business Segment
- Table 97: Roche: Financials, 2021
- Table 98: Roche: Financial Performance, 2018-2020
- Table 99: Roche: Revenues, by Segment, 2016-2018
- Table 100: Roche: Revenues, by Diagnostic Segment, 2016-2018
- Table 101: Roche: Product Portfolio
- Table 102: Roche: Diagnostics Patient Monitoring Product Portfolio
- Table 103: Roche: Oncology Pharmaceuticals Product Portfolio
- Table 104: Roche: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 105: Roche: Key Developments
- Table 106: Sanofi: Business Segment
- Table 107: Sanofi: Financial Performance, 2021
- Table 108: Sanofi: Oncology Pharmaceuticals Product Portfolio
- Table 109: Sanofi: Oncology Pharmaceuticals Revenue, 2018-2020
- Table 110: Servier: Key Financials, 2021

- Table 111: Shionogi: Key Financials, 2021
- Table 112: Sinopharm: Key Financials, 2021
- Table 113: Stada Arzneimittel: Key Financials, 2021
- Table 114: Sumitomo Dainippon Pharma: Key Financials, 2021
- Table 115: Sun Pharmaceutical: Key Financials, 2021
- Table 116: Takeda: Oncology Pharmaceuticals Product Portfolio
- Table 117: Takeda: Oncology Pharmaceuticals Revenue, 2019-2021
- Table 118: Takeda: Key Financials, 2021
- Table 119: Teva: Key Financials 2021
- Table 120: UCB: Key Financials, 2021
- Table 121: Vertex: Key Financials, 2021
- Table 122: Vertex: Recent Developments
- Table 123: Viatris: Top Product Portfolio
- Table 124: Viatris: Key Financials, 2021
- Table 125: Viatris: Key Developments

## List Of Figures

### LIST OF FIGURES

- Figure 1: Stakeholders Involved in the Innovation Process
- Figure 2: Trends in Per Capita Real Gross Domestic Product Growth, by Region, 2016-2019
- Figure 3: Global Age 60+ Population, by Region, 2015-2050
- Figure 4: Global Projected Growth Rate, Diabetes and Impaired Glucose Tolerance in Patients Aged, 20-79 Years, 2010 and 2030
- Figure 5: Global Company Market Shares of Pharmaceutical Drugs, 2021
- Figure 6: Abbott: Revenue Share, by Region/Country, 2021
- Figure 7: Abbott: Revenue Share, by Business Segment, 2021
- Figure 8: Abbott: R&D Expenditure, 2015-2021
- Figure 9: AbbVie: Hematologic Oncology Annual Revenue, 2018-2021
- Figure 10: AbbVie Inc.: Net Revenue Share, by Business Segment, 2021
- Figure 11: AbbVie Inc.: Net Revenue Share, by Region, 2021
- Figure 12: AbbVie Inc.: Revenue Share, by Country, 2021
- Figure 13: Alexion: Net Revenue Share, by Business Segment, 2020
- Figure 14: Alexion: Net Revenue Share, by Region/Country, 2020
- Figure 15: Amgen: Oncology Pharmaceuticals Annual Revenue, 2018-2020
- Figure 16: Amgen: Sales Share, by Product, 2021
- Figure 17: Amgen: Revenue Share, by Region, 2021
- Figure 18: Astellas: Oncology Pharmaceuticals Annual Revenue, 2018-2020
- Figure 19: AstraZeneca: Sales Share, by Segment, 2021
- Figure 20: AstraZeneca: Revenue Share, by Region, 2021
- Figure 21: AstraZeneca: Oncology Pharmaceuticals Segment Annual Revenue, 2018-2021
- Figure 22: Aurobindo Pharma: Net Revenue Share, by Region/Country, 2021
- Figure 23: Bausch Health Companies Inc.: Annual Revenue, 2017-2021
- Figure 24: Bausch Health Companies Inc.: Revenue Share, by Segment, 2021
- Figure 25: Bayer AG: Oncology Pharmaceuticals Annual Revenue, 2018-2020
- Figure 26: Bayer AG: Oncology Pharmaceuticals Annual Revenue, 2018-2020
- Figure 27: Bayer AG: Revenue Share, by Region, 2021
- Figure 28: Bayer AG: Revenue Share, by Business Segment, 2021
- Figure 29: Biogen: Sales Share, by Product, 2021
- Figure 30: Biogen: Revenue Share, by Region/Country, 2021
- Figure 31: Boehringer Ingelheim: Annual Revenue, 2021
- Figure 32: Boehringer Ingelheim: Revenue Share, by Business Segment, 2021

- Figure 33: Boehringer Ingelheim: Revenue Share, by Region, 2021
- Figure 34: Bristol Myers Squibb: Sales Share, by Product, 2021
- Figure 35: Bristol-Myers Squibb: Total Revenue Share, by Region/Country, 2021
- Figure 36: Bristol-Myers Squibb: Oncology Pharmaceuticals Annual Revenue, 2018-2020
- Figure 37: CSL Ltd. (Seqirus): Net Revenue, 2017-2021
- Figure 38: CSL Ltd.: Revenue Share, by Business Segment, 2021
- Figure 39: Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Segment, 2018
- Figure 40: Dr. Reddy's: Revenue Share, by Business Segment, 2021
- Figure 41: Eli Lilly and Co.: Total Sales Share, by Product Segment, 2020
- Figure 42: Eli Lilly and Co.: Revenue Share, by Product, 2020
- Figure 43: Eli Lilly and Co.: Oncology Annual Revenue, 2018-2020
- Figure 44: Eli Lilly and Co.: Total Revenue Share, by Region, 2020
- Figure 45: Endo International: Revenue Share, by Business Segment, 2021
- Figure 46: Endo International: Total Revenue Share, by Region, 2021
- Figure 47: Gilead Sciences Inc.: Oncology Pharmaceuticals Annual Revenue, 2018-2020
- Figure 48: Gilead Sciences: Revenue Share, by Business Segment, 2021
- Figure 49: Gilead Sciences: Total Revenue Share, by Region/Country, 2021
- Figure 50: GlaxoSmithKline PLC: Net Revenue, 2016-2021
- Figure 51: GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2021
- Figure 52: GlaxoSmithKline PLC: Revenue Share, by Region/Country, 2021
- Figure 53: Grifols SA: Annual Revenue, 2018-2021
- Figure 54: Grifols SA: Revenue Share, by Segment, 2021
- Figure 55: Grifols SA: Revenue Share, by Region/Country, 2021
- Figure 56: Lundbeck: Revenue Share, by Business Segment, 2021
- Figure 57: Lundbeck: Total Revenue Share, by Region, 2021
- Figure 58: Incyte: Revenue Share, by Business Segment, 2021
- Figure 59: Johnson & Johnson: Financials, 2017-2021
- Figure 60: Johnson & Johnson: Total Sales Share, by Business Segment, 2021
- Figure 61: Johnson & Johnson: Total Revenue Share, by Region/Country, 2021
- Figure 62: Mallinckrodt: Revenue Share, by Business Segment, 2021
- Figure 63: Mallinckrodt: Total Revenue Share, by Region/Country, 2021
- Figure 64: Menarini Group: Revenue Share, by Business Segment, 2021
- Figure 65: Menarini Group: Total Revenue Share, by Region/Country, 2021
- Figure 66: Merck & Co. Inc.: Revenue Share, by Business Segment, 2021
- Figure 67: Merck & Co. Inc.: Revenue Share, by Region/Country, 2021
- Figure 68: Merck KGaA: Revenue Share, by Business Segment, 2021
- Figure 69: Merck KGaA: Total Revenue Share, by Region, 2021

- Figure 70: Novartis: Oncology Pharmaceuticals Segment Annual Revenue, 2018-2020
- Figure 71: Novartis: Revenue Share, by Business Segment, 2021
- Figure 72: Novartis: Total Revenue Share, by Region, 2021
- Figure 73: Novo Nordisk: Revenue Share, by Region, 2021
- Figure 74: Novo Nordisk: Revenue Share, by Business Segment, 2021
- Figure 75: Otsuka Holdings Co. Ltd.: Annual Revenue, 2018-2021
- Figure 76: Otsuka Holdings Co. Ltd.: Revenue Share, by Segment, 2020
- Figure 77: Pfizer: Oncology Segment Annual Revenue, 2018-2020
- Figure 78: Pfizer: Revenue Share, by Region/Country, 2021
- Figure 79: Pfizer: Revenue Share, by Business Segment, 2021
- Figure 80: Regeneron: Revenue Share, by Business Segment, 2021
- Figure 81: Roche: Revenue Share, by Segment, 2021
- Figure 82: Roche: Total Sales Share, by Product Segment, 2020
- Figure 83: Roche: Oncology Annual Revenue, 2018-2020
- Figure 84: Sanofi: Net Sales Share, by Business Segment, 2021
- Figure 85: Sanofi: Net Sales Share, by Region/Country, 2021
- Figure 86: Sanofi: Oncology Pharmaceuticals Annual Revenue, 2018-2020
- Figure 87: Servier: Revenue Share, by Business Segment, 2021
- Figure 88: Servier: Total Revenue Share, by Region, 2021
- Figure 89: Stada Arzneimittel: Revenue Share, by Business Segment, 2021
- Figure 90: Stada Arzneimittel: Total Revenue Share, by Region/Country, 2021
- Figure 91: Sumitomo Dainippon Pharma: Revenue Share, by Business Segment, 2021
- Figure 92: Sun Pharmaceutical: Revenue Share, by Business Segment, 2021
- Figure 93: Sun Pharmaceutical: Total Revenue Share, by Region/Country, 2021
- Figure 94: Takeda: Oncology Pharmaceuticals Annual Revenue, 2018-2020
- Figure 95: Takeda: Revenue Share, by Business Segment, 2021
- Figure 96: Takeda Pharmaceutical: Total Revenue Share, by Region/Country, 2021
- Figure 97: Teva: Annual Revenue, 2018-2020
- Figure 98: Teva: Revenue Share, by Business Segment, 2021
- Figure 99: Teva: Total Revenue Share, by Region, 2021
- Figure 100: UCB: Revenue Share, by Business Segment, 2021
- Figure 101: UCB: Total Revenue Share, by Region, 2021
- Figure 102: Vertex: Revenue Share, by Business Segment, 2021
- Figure 103: Vertex: Total Revenue Share, by Region/Country, 2021
- Figure 104: Viatrix: Annual Revenue, 2018-2021
- Figure 105: Viatrix: Revenue Share, by Product Category, 2021

## I would like to order

Product name: Pharmaceutical Drugs Industry: Global Competitive Landscape 2021

Product link: <https://marketpublishers.com/r/P86397F0122AEN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P86397F0122AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970